Skip to content

Effects of different ERAS regimens on prognosis of elderly intertrochanteric fractures

Effects of different ERAS regimens on prognosis of elderly intertrochanteric fractures

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055281
Enrollment
Unknown
Registered
2022-01-05
Start date
2020-11-18
Completion date
Unknown
Last updated
2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

femoral intertrochanteric fracture

Interventions

Group 1:Modified ERAS pathway
Group 2:Traditional ERAS pathway

Sponsors

Guangzhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 60 years, gender is not limited; 2. According to clinical diagnosis or imaging diagnosis, patients who meet the diagnostic conditions of intertrochanteric fractures require hospitalization and surgical treatment; 3. Injury time (from the time of injury reported by the subject or his family to the time of admission) < 21 days; 4. The subjects or their legal representatives can understand the purpose of the research, show sufficient compliance with the research protocol, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Systemic or local infection at the surgical site; 2. Multiple injuries; 3. Stroke in the past 3 months, or myocardial infarction within 6 months, or active bleeding disease; 4. Ischemic disease or arthritis in the hip joint of the previous diseased side; 5. There is a clinical or imaging diagnosis of pathological fracture or a high risk of impending fracture; 6. There is failure of important organs and there is no effective alternative treatment; 7. Advanced malignant tumor or tumor bone metastasis at the injury site; 8. Severe malnutrition (BMI = 35); 9. Open fracture; 10. Long-term use of glucocorticoid drugs; 11. Combined with other diseases, the researchers believe that it is not suitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
1-year mortality;

Secondary

MeasureTime frame
daily living ability score;incidence of adverse events during hospitalization;

Countries

China

Contacts

Public ContactYang Yunfa

Guangzhou First People's Hospital

yangyunfamd@163.com+86 20 81048245

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026